Is REGN a good stock to buy? We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. on Ocular Capital’s Substack. In this article, we will summarize the bulls’ thesis on REGN. Regeneron Pharmaceuticals, Inc.'s share was trading at $774.66 as of March 11th. REGN’s trailing and forward P/E were 18.68 and 18.05, respectively according to Yahoo Finance.
[caption id="attachment_575380" align="aligncenter" width="750"]Regeneron Pharmaceuticals, Inc. (REGN) stands out as a powerful innovation engine within the...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.